Eli Lilly Launches Phase III Trial of Next-Generation FRα ADC LY4170156 for Ovarian Cancer

▎Armstrong

On October 9, 2025, Eli Lilly and Company registered a Phase III clinical trial, FRAmework-01, on Clinicaltrials.gov for the new FRα ADC drug LY4170156 in treating platinum-resistant or platinum-sensitive ovarian cancer.

This Phase III clinical trial plans to enroll 1,080 patients with advanced ovarian cancer and is expected to be preliminarily completed by April 2028.

At the ASCO meeting in June this year, Eli Lilly and Company announced the preliminary clinical data of LY4170156. Among 58 evaluable patients, the ORR was 45%, and the DCR was 74%. In the 20 patients receiving the RP2D dose of 4mg/kg, the ORR reached 55%. More importantly, LY4170156 demonstrated promising efficacy and tolerability in patients with different FRα expression levels.

Summary

AbbVie's FRα ADC has been approved for marketing, but it is only for patients with high FRα expression. The competition for the new generation of FRα ADCs is particularly intense, including Genmab/ProfoundBio's FRα ADC, AbbVie's FRα bispecific epitope ADC, Eli Lilly's FRα ADC, etc.